GET DAILY SIGNALSUnicycive Therapeutics (UNCY): Tracking a Clinical-Stage Kidney Disease Biotech
Key Takeaways
- UNCY is the ticker for Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for kidney diseases.
- The company is headquartered in Mountain View, California, and listed on the Nasdaq Capital Market following its initial public offering (IPO) in 2021.
- Its lead product candidate, oxylanthanum carbonate (OLC), is an oral phosphate binder designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
- A second candidate, UNI-494, is being developed for conditions related to acute kidney injury.
- As a clinical-stage biotech, the company generates little or no product revenue and relies on capital raised from investors to fund research, development, and regulatory work.
A Closer Look at Unicycive Therapeutics
UNCY represents Unicycive Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for patients with kidney disease. Investors follow the stock because of its lead drug candidate's potential to address a large, well-defined patient population and because regulatory milestones can meaningfully shape the company's outlook. Understanding UNCY requires a look at its pipeline, its approach to drug development, and the financial profile of an early-stage biopharmaceutical business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background and Operations
Unicycive Therapeutics was incorporated in 2016 and is headquartered in Mountain View, California. The company completed its IPO in July 2021, with its common stock beginning to trade on the Nasdaq Capital Market under the symbol UNCY. Like many biotechnology firms, Unicycive operates a research-and-development-driven business model: it invests heavily in preclinical and clinical testing, regulatory submissions, and manufacturing readiness in pursuit of regulatory approval and eventual commercialization of its drug candidates.
The company's lead product candidate is oxylanthanum carbonate (OLC), an investigational oral phosphate binder being developed for the treatment of hyperphosphatemia, a condition in which too much phosphate builds up in the blood, commonly seen in patients with chronic kidney disease (CKD) who are on dialysis. OLC uses proprietary nanoparticle technology that the company says delivers high phosphate-binding potency while reducing the number and size of pills patients must take each day. Unicycive is seeking U.S. Food and Drug Administration (FDA) approval of OLC through the 505(b)(2) regulatory pathway, a route that can allow a drug to rely in part on existing data for a reference product.
The company's second investigational treatment, UNI-494, is a nicotinamide ester derivative being developed for conditions related to acute kidney injury. It has received orphan drug designation from the FDA for the prevention of delayed graft function in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
Because Unicycive is clinical-stage, it has not yet generated meaningful revenue from product sales. Its financial profile reflects ongoing research and development spending and net losses, funded primarily through equity offerings and its cash position.
What Draws Investor Attention to UNCY
Investor attention on Unicycive centers largely on the regulatory progress and commercial potential of OLC. Hyperphosphatemia affects a substantial share of dialysis patients, and the company describes an opportunity to offer a lower-pill-burden option that could improve patient adherence compared with existing phosphate binders. A successful approval and launch would represent a transition from a development-stage company to one with a commercial product, a meaningful inflection point for any biotech. From what I see, the broader pipeline—including UNI-494 for acute kidney injury—offers additional, longer-term growth opportunities. The company also highlights a global patent portfolio for OLC, including composition-of-matter patents, which can help protect a product's market position if it reaches commercialization.
Risks and Key Considerations
Investing in Unicycive carries risks typical of clinical-stage biotechnology companies. The most significant is regulatory uncertainty: the company has received Complete Response Letters (CRLs) from the FDA related to third-party manufacturing, although the agency has not raised concerns about OLC's clinical efficacy or safety data. Approval is not guaranteed, and any further delays could affect the company's timeline and capital needs.
Additional risks include the absence of commercial revenue, ongoing operating losses, and the possibility that the company may need to raise additional capital to fund development and a potential launch. Unicycive also faces competition from established phosphate-binder therapies and other biotech developers, and its future depends on successful commercialization, which requires building or accessing sales, marketing, and distribution capabilities. Investors should consider these factors alongside the company's relatively small size and early-stage financial profile.
Conclusion
Unicycive Therapeutics is a clinical-stage biopharmaceutical company working to address significant unmet needs in kidney disease care, led by its phosphate-binder candidate OLC and an earlier-stage program in acute kidney injury. Its investment profile is defined by pipeline progress, regulatory milestones, and the potential transition to commercialization rather than by current revenue. For investors, UNCY offers exposure to a focused biotech story whose market position will ultimately depend on regulatory outcomes and successful product launch. I’m watching this closely as the next regulatory steps unfold.
Exploring Tickeron’s AI Screener
In my own research process, Tickeron’s AI Screener has become a useful resource for quickly scanning technical indicators, fundamentals, and industry patterns across thousands of stocks. It helps narrow broad market data into focused watchlists that align with specific strategies, which I find practical when evaluating names like UNCY alongside peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Momentum Indicator for UNCY turns positive, indicating new upward trend
UNCY saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In 87 of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UNCY's RSI Oscillator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 72 cases where UNCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for UNCY just turned positive on October 22, 2026. Looking at past instances where UNCY's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
Following a +6.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNCY advanced for three days, in 209 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UNCY entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.856) is normal, around the industry mean (3.498). P/E Ratio (-2.029) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (39.216) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. UNCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement